3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Phase 1
1
Status
Recruiting
3
Active not recruiting
3
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Genitourinary
3
Conditions
Prostatic Neoplasms
3
Ovarian Neoplasms
2
Neoplasms
2
Endometrial Neoplasms
2
Small Cell Lung Carcinoma
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Carcinoma, Non-Small-Cell Lung
1
Bulbo-Spinal Atrophy, X-Linked
1
Breast Neoplasms
1
Advanced Breast Cancer
1
Adenocarcinoma of Lung
1
Interventions
Magnetic Resonance Spectroscopy
51
Specimen Handling
42
enzalutamide
36
Androgen Antagonists
35
Radiosurgery
33
Radiotherapy
31
darolutamide
26
Prednisone
26
Abiraterone Acetate
25
Leuprolide
22
Docetaxel
22
apalutamide
21
abiraterone
19
Pluvicto
19
Standard of Care
18
Triptorelin Pamoate
17
Radiation
17
Biopsy
16
relugolix
15
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
15
Goserelin
14
Blood Specimen Collection
13
gallium 68 PSMA-11
12
X-Rays
11
Surveys and Questionnaires
11
pembrolizumab
10
luprolide acetate gel depot
10
Carboplatin
10
Methods
9
Interviews as Topic
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Recruiting
×
Prostatic Neoplasms
×
AZD5305
×
Clear all
NCT06952803
2026-05-19
EvoPAR-PR02
AstraZeneca
Phase 3
Recruiting
700 enrolled
NCT07336446
2026-05-01
ANDROMEDA
AstraZeneca
Phase 1/2
Recruiting
300 enrolled
NCT05938270
2026-02-24
ASCERTAIN
AstraZeneca
Phase 1
Recruiting
120 enrolled